Literature DB >> 3071139

Captopril-induced metabolic acidosis with hyperkalemia.

T Sakemi1, N Ohchi, T Sanai, O Rikitake, T Maeda.   

Abstract

Hyperreninemic hypoaldosteronism was diagnosed in a 34-year-old woman with hypertension who was receiving captopril therapy. Renal biopsy revealed an advanced stage of IgA nephropathy, and her creatinine clearance was 40 ml/min. Elevation of serum potassium from 4.7 to 5.8 mEq/l and development of hyperchloremic metabolic acidosis with laboratory findings of pH 7.285, HCO3- 13.5 mEq/l, Na 141, and Cl 114 mEq/l were observed after captopril therapy. When captopril was withdrawn, elevated serum potassium levels and metabolic acidosis returned to normal. Challenge with captopril resulted in a decrease in plasma aldosterone levels, an increase in plasma renin activity, and development of hyperkalemic, hyperchloremic metabolic acidosis which is corrected with mineralocorticoid replacement. This case study demonstrates that captopril can cause hyperreninemic hypoaldosteronism with the laboratory finding of hyperkalemic, hyperchloremic metabolic acidosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3071139     DOI: 10.1159/000167591

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  4 in total

Review 1.  Pharmacologically-induced metabolic acidosis: a review.

Authors:  George Liamis; Haralampos J Milionis; Moses Elisaf
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

Review 2.  Drug-induced acid-base disorders.

Authors:  Daniel Kitterer; Matthias Schwab; M Dominik Alscher; Niko Braun; Joerg Latus
Journal:  Pediatr Nephrol       Date:  2014-11-05       Impact factor: 3.714

3.  ACE-inhibitors-induced metabolic acidosis in a child with nephrotic syndrome.

Authors:  Irene Bruno; Marco Pennesi; Federico Marchetti
Journal:  Pediatr Nephrol       Date:  2003-10-24       Impact factor: 3.714

4.  Renal effects of angiotensin converting enzyme inhibitors: nondiabetic chronic renal disease.

Authors:  J A Opsahl; P A Abraham; W F Keane
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.